Elixiron Immunotherapeutics (China) Ltd announced that it has raised $27 million in a round of funding led by new investor Pangu Capital and returning investor Taiwania Capital on August 23, 2021. The transaction included participation from new investors DCI Partners, Mega International Commercial Bank, Fubon Financial Holdings Hong Tai Electric Industrial, as well as other existing investors such as China Development Capital Industrial Bank (CDIB) Capital Group.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
38.95 TWD | -3.47% | +0.91% | +37.63% |
1st Jan change | Capi. | |
---|---|---|
+37.63% | 381M | |
+44.04% | 17.09B | |
+40.95% | 5.13B | |
-2.20% | 4.72B | |
+31.59% | 4.52B | |
+10.41% | 4.48B | |
+29.75% | 4.38B | |
+16.41% | 4.07B | |
+88.63% | 3.53B | |
+85.02% | 2.54B |
- Stock Market
- Equities
- 1612 Stock
- News Hong Tai Electric Industrial Co., Ltd.
- Elixiron Immunotherapeutics Ltd announced that it has received $27 million in funding from a group of investors